{
    "name": "terlipressin",
    "comment": "Rx",
    "other_names": [
        "Terlivaz"
    ],
    "classes": [
        "Vasopressin-Related"
    ],
    "source": "https://reference.medscape.com/drug/terlivaz-terlipressin-4000107",
    "pregnancy": {
        "common": [
            "May cause fetal harm, based on its mechanism of action and findings in published literature",
            "In small, published studies, administration of a single IV dose to pregnant females during the first trimester induced uterine contractions and endometrial ischemia",
            "Limited published data are not sufficient to determine drug-associated risk for major birth defects or miscarriage",
            "Inform pregnant patients of potential risk to fetus"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Administration to pregnant guinea pigs at doses lower than the maximum recommended human dose of 4 mg/day caused a marked decrease in uterine and placental blood flow",
                    "In rabbits, it is both embryotoxic and teratogenic (increased resorptions, increased implantation loss, fetal anomalies and fetal deformities)"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available regarding presence in human or animal milk, effects on breastfed infants, or effect on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Serious or fatal respiratory failure",
                    "description": [
                        "May cause serious or fatal respiratory failure",
                        "Patients with volume overload or with acute-on-chronic liver failure (ACLF) Grade 3 are at increased risk",
                        "Assess oxygenation saturation (eg, SpO2) before initiating",
                        "Do not initiate in patients experiencing hypoxia (eg, SpO2 <90%) until oxygenation levels improve",
                        "Monitor for hypoxia using continuous pulse oximetry during treatment and discontinue if SpO2 decreases below 90%"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Patients experiencing hypoxia or worsening respiratory symptoms",
                "Patients with ongoing coronary, peripheral, or mesenteric ischemia"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "May cause fetal harm when administered to pregnant females; terlipressin induces uterine contractions and endometrial ischemia in both humans and animals",
                "May cause cardiac, cerebrovascular, peripheral, or mesenteric ischemia; avoid with history of severe cardiovascular conditions, cerebrovascular, and ischemic disease; discontinue signs or symptoms suggestive of ischemic adverse reactions occur"
            ],
            "specific": [
                {
                    "type": "Serious or fatal respiratory failure",
                    "description": [
                        "May cause serious or fatal respiratory failure",
                        "Obtain baseline SpO2 and do not initiate in hypoxic patients",
                        "Monitor for changes in respiratory status using continuous pulse oximetry and regular clinical assessments",
                        "Discontinue if hypoxia or increased respiratory symptoms occur",
                        "Fluid overload may increase risk; manage intravascular volume overload by reducing or discontinuing albumin and/or other fluids and judicious diuretic use",
                        "Temporarily interrupt, reduce, or discontinue treatment until volume status improves",
                        "Avoid use in patients with ACLF Grade 3 because they are at significant risk for respiratory failure "
                    ]
                },
                {
                    "type": "Ineligibility for liver transplant",
                    "description": [
                        "Terlipressin-related adverse reactions (respiratory failure, ischemia) may make patients ineligible for liver transplantation (if listed)",
                        "For patient with high prioritization for liver transplantation (eg, MELD â‰¥35), benefits of terlipressin may not outweigh risks"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Abdominal pain",
            "percent": "19.5"
        },
        {
            "name": "Nausea",
            "percent": "16"
        },
        {
            "name": "Respiratory failure",
            "percent": "15.5"
        },
        {
            "name": "Diarrhea",
            "percent": "13"
        },
        {
            "name": "Dyspnea",
            "percent": "12.5"
        },
        {
            "name": "Fluid overload",
            "percent": "8.5"
        },
        {
            "name": "Pleural effusion",
            "percent": "5.5"
        },
        {
            "name": "Sepsis",
            "percent": "5.5"
        },
        {
            "name": "Bradycardia",
            "percent": "5"
        },
        {
            "name": "Ischemia",
            "percent": "4.5"
        },
        {
            "name": "related events",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Hyponatremia",
            "percent": null
        },
        {
            "name": "Skin necrosis and gangrene",
            "percent": null
        }
    ]
}